Eli Lilly and Company 10-Kyear ended 2025-12-31

Executive Summary

Eli Lilly’s FY2025 revenue rose 45% to $65.2B as Mounjaro and Zepbound drove rapid volume growth, lifting GAAP net income 95% to $20.6B despite lower realized U.S. prices. The two medicines now generate 56% of revenue, making Lilly’s growth unusually dependent on sustained demand, access and manufacturing execution in cardiometabolic care. Lilly is investing heavily in capacity and its pipeline; operating cash flow increased, but capital spending and shareholder returns exceeded internally generated free cash flow. For investors, the opportunity is further volume growth from expanded supply, markets and indications, while the key test is whether those gains outweigh pricing concessions and the costs of expansion.

Key Financial Highlights

• Revenue mix: Mounjaro generated $23.0B, +99% Y/Y, and Zepbound $13.5B, +175%; together they represented 56% of revenue. Cardiometabolic medicines generated $48.2B, ≈74% of revenue. U.S. volume rose 53% while realized prices fell 10%.
• Earnings quality: Operating cash flow trailed net income as receivables, inventory and prepaid assets grew, partly offset by higher payables and other liabilities. Capital expenditures rose to $7.84B from $5.06B, principally for manufacturing.
• Capital allocation: Repurchases totaled $4.11B, while shares outstanding fell only from 947.9M to 944.8M; Lilly also paid $5.38B in dividends. Combined dividends and repurchases exceeded free cash flow. Interest expense rose to $895M from $781M.
• Investment and taxes: Research and development expense rose to $13.3B; acquired in-process research and development charges were $2.91B. The effective tax rate increased to 19.8% from 16.5%, while $10.8B of cash tax payments contributed to $12.9B of prepaid taxes.
• Nonrecurring revenue: Jardiance’s $3.43B included a $370M benefit from changed commercialization responsibilities and a $200M sales-based milestone; those items should not be extrapolated as recurring product demand.

Business Developments

Lilly is allocating capital toward cardiometabolic supply and future launches, expanding manufacturing in the U.S. and Europe. Construction in progress increased to $13.0B from $8.25B, and inventory included $1.5B capitalized before launch, primarily for orforglipron. This positions Lilly to serve demand but commits resources before all regulatory and commercial outcomes are known.

Lilly submitted orforglipron for obesity review in the U.S., EU and Japan and for type 2 diabetes in the EU; it also submitted insulin efsitora alfa in those three markets. Its broader pipeline and approvals across oncology, immunology and neuroscience offer diversification, although current growth remains concentrated in cardiometabolic products. LillyDirect is a growing direct-to-patient channel that may widen access where insurance coverage is limited.

Preliminary U.S. government agreements announced in November 2025 pair lower prices for certain patients with potentially broader access. Lilly expects discounted Medicare access to its obesity medicines by 07/01/2026, but definitive terms remain under negotiation; additional patients may not offset lower prices per prescription.

Risk Assessment

• Product concentration and competition: Mounjaro and Zepbound account for 56% of revenue, amplifying the effect of rival treatments, access restrictions, safety concerns or weaker demand.
• Pricing and reimbursement: U.S. realized prices fell 10% despite volume growth; Jardiance faces a 2026 Medicare price set at a 66% discount to its 2023 list price, while Trulicity and Verzenio face government-set pricing in 2028.
• Manufacturing and launch execution: Rapid expansion and reliance on specialized suppliers create shortage, quality and underutilization risks; certain supply arrangements could require payments of up to $10B if specified purchases are not made.
• Pipeline and exclusivity: Orforglipron’s approval and uptake are uncertain despite pre-launch investment, while Trulicity is expected to lose significant protection in the next few years.
• Rebates and estimates: Sales rebate and discount liabilities reached $17.4B, and a 5% change in the consolidated liability would affect revenue by $897M; the auditor identified these accruals as a critical audit matter.
• Litigation and regulation: Incretin product-liability claims, pricing and 340B disputes, and predominantly self-insured product litigation could produce material charges in individual periods.
• Operational concentration and security: Three wholesalers each generated 16%–24% of revenue; a distributor disruption or cyber incident affecting Lilly or its providers could interrupt sales, manufacturing or sensitive-data systems.

Strategic Outlook and Investor Actionables

Lilly’s near-term thesis is that new capacity, international uptake and additional cardiometabolic indications can sustain volume-led growth while its pipeline broadens future options. The counterweight is rising exposure to net-price declines, execution delays and capital intensity.

• Demand vs price: Track Mounjaro and Zepbound revenue, U.S. volume growth and realized-price changes; continued volume gains must outweigh concessions.
• Capacity and cash: Track launches, inventory, capital expenditures and free cash flow; improving supply without persistent inventory buildup would support returns on expansion.
• Access and pipeline: Track final government pricing terms, Medicare obesity-drug access and orforglipron’s regulatory outcome; uptake at acceptable net prices would validate the next leg of growth.